Business

Announcement on Voluntary Disclosure of European Commission's Approval of Baize'an (Tislelizumab Injection) for First-line and Second-line Treatment of Three Non-small Cell Lung Cancer Indications

Announcement on Voluntary Disclosure of European Commission's Approval of Baize'an (Tislelizumab Injection) for First-line and Second-line Treatment of Three Non-small Cell Lung Cancer Indications

articleBeone Medicines Ltd. Class AApril 23, 20244/news/announcement-on-voluntary-disclosure-of-european-commissions-approval-of-baizean-tislelizumab-injection-for-first-line-and-second-line-treatment-of-three-non-small-cell-lung-cancer-indications
Announcement on Voluntary Disclosure of European Commission's Approval of Baize'an (Tislelizumab Injection) for First-line and Second-line Treatment of Three Non-small Cell Lung Cancer Indications

About this update from Beone Medicines Ltd. Class A

Announcement on Voluntary Disclosure of European Commission's Approval of Baize'an (Tislelizumab Injection) for First-line and Second-line Treatment of Three Non-small Cell Lung Cancer IndicationsThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference:" target="_blank">View Attachment

View stock analysis, news, and events for Beone Medicines Ltd. Class A